SEC Company Response from MediWound Ltd. (MDWD) (CIK 0001593984) (MDWD) — Apr 18, 2019
MediWound Ltd. (MDWD) (CIK 0001593984)
Date: April 18, 2019 · CIK: 0001593984 · Accession: 0001178913-19-001183
AI Filing Summary & Sentiment
File numbers found in text: 333-230490
Letter
Via EDGAR Transmission Division of Corporation Finance Securities and Exchange Commission MediWound Ltd. Registration Statement on Form F-3 Filed March 25, 2019 Registration No. 333-230490
Dear Ms. Aldave:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on April 22, 2019 at 4:00 p.m. Eastern Time or as soon thereafter as practicable, or at such later time as MediWound Ltd. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Gilad Zohari at (212) 906-4667, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
MediWound Ltd.
Show Raw Text
CORRESP 1 filename1.htm MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel April 18, 2019 Via EDGAR Transmission Tonya K. Aldave, Esq. Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MediWound Ltd. Registration Statement on Form F-3 Filed March 25, 2019 Registration No. 333-230490 Dear Ms. Aldave: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on April 22, 2019 at 4:00 p.m. Eastern Time or as soon thereafter as practicable, or at such later time as MediWound Ltd. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Gilad Zohari at (212) 906-4667, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, MediWound Ltd. By: /s/ Sharon Malka Name: Sharon Malka Title: Chief Financial and Operations Officer cc: Nathan Ajiashvili, Latham & Watkins LLP